Business
PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure Committee
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. ...
About this update from Preveceutical Medical Inc
[{"type":"text","content":"PreveCeutical Initiates Non-Analgesic (Painkiller) Program, Clinical Development Program & Disclosure CommitteeVancouver, British Columbia--(Newsfile Corp. - March 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the \"Company\" or \"PreveCeutical\"), is pleased to announce that PreveCeutical commenced clinical work with our selected clinical research organization (CRO) as announced on February 7, 2023, to complete the following.Conduct a comprehensive gap analysis to both confirm current conclusions as well as identify any potential additional nonclinical studies (beyond those already underway or in the planning stage) that will be needed to support a successful initial IND and/or CTA submission.Construction of a clinical development plan for Phase 1 through pivotal Phase 3 studies.Authoring of the Investigational Brochure for the Client's lead peptide in the final indication of interest.PreveCeutical has now commenced the clinical development on March 20, 2023. This work is being performed at our selected CRO's facilities in Australia.Furthermore, the board of directors appointed a disclosure committee represented by Stephen Van Deventer, Dr Linnea Olofsson and Evan Ballantyne effective immediately.PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, \"As we continue to meet further milestones, we are enthusiastic that this program has commenced as we plan to aggressively pursue the development so we may apply for IND (Investigative New Drug) status and complete the Phase 1 clinical trials.\"About PreveCeuticalPreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector. With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.For more information about PreveCeutical, please visit our website, www.PreveCeutical.com or follow us on Twitter and Facebook. On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive OfficerFor fur...